BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28780352)

  • 1. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
    Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G
    Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression.
    Yang L; Zhu JY; Zhang JG; Bao BJ; Guan CQ; Yang XJ; Liu YH; Huang YJ; Ni RZ; Ji LL
    Tumour Biol; 2016 Mar; 37(3):4115-26. PubMed ID: 26490982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.
    Zhang K; Chen H; Wu G; Chen K; Yang H
    Med Oncol; 2014 Nov; 31(11):247. PubMed ID: 25260803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of Far Upstream Element-Binding Protein 1 (FUBP1) Promotes Tumor Proliferation and Tumorigenesis of Clear Cell Renal Cell Carcinoma.
    Duan J; Bao X; Ma X; Zhang Y; Ni D; Wang H; Zhang F; Du Q; Fan Y; Chen J; Wu S; Li X; Gao Y; Zhang X
    PLoS One; 2017; 12(1):e0169852. PubMed ID: 28076379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
    Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
    Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of far upstream element-binding protein 1 (FUBP1) promotes tumor proliferation and unfavorable prognosis in tongue squamous cell carcinoma.
    Chen Y; Liu J; Geng N; Feng C
    Int J Biol Markers; 2020 Jun; 35(2):56-65. PubMed ID: 32339054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.
    Chen K; Mo J; Zhou M; Wang G; Wu G; Chen H; Zhang K; Yang H
    Med Oncol; 2014 Apr; 31(4):886. PubMed ID: 24535608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of Sam68 in sacral chordomas is associated with worse clinical outcomes.
    Wen H; Li P; Ma H; Zheng J; Yu Y; Lv G
    Onco Targets Ther; 2017; 10():4691-4700. PubMed ID: 29026317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
    Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
    J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma.
    Zhou M; Chen K; Yang H; Wang G; Lu J; Ji Y; Wu C; Chen C
    J Neurooncol; 2014 Jan; 116(1):77-82. PubMed ID: 24135846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAM10 Is a Potential Novel Prognostic Biomarker for Sacral Chordoma.
    Ding Y; Bui MM; Wang Q; Sun X; Zhang M; Niu X; Tian W
    Ann Clin Lab Sci; 2019 May; 49(3):309-316. PubMed ID: 31308029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
    Luo P; Wang X; Zhou J; Li L; Jing Z
    Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low expression of PHLPP1 in sacral chordoma and its association with poor prognosis.
    Chen H; Zhang K; Wu G; Song D; Chen K; Yang H
    Int J Clin Exp Pathol; 2015; 8(11):14741-8. PubMed ID: 26823799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA KRT8P41/miR-193a-3p/FUBP1 axis modulates the proliferation and invasion of chordoma cells.
    Wen H; Fu Y; Zhu Y; Tao S; Shang X; Li Z; You T; Zhang W
    J Bone Oncol; 2021 Dec; 31():100392. PubMed ID: 34712553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
    Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP
    J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of survivin in sacral chordoma.
    Chen C; Yang HL; Chen KW; Wang GL; Lu J; Yuan Q; Gu YP; Luo ZP
    Med Oncol; 2013 Jun; 30(2):529. PubMed ID: 23504337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
    Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
    Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence.
    Li X; Wang S; Chen Y; Liu G; Yang X
    Onkologie; 2013; 36(10):567-71. PubMed ID: 24107910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Far upstream element -binding protein 1 (FUBP1) participates in the malignant process and glycolysis of colon cancer cells by combining with c-Myc.
    Wang S; Wang Y; Li S; Nian S; Xu W; Liang F
    Bioengineered; 2022 May; 13(5):12115-12126. PubMed ID: 35546072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The master regulator FUBP1: its emerging role in normal cell function and malignant development.
    Debaize L; Troadec MB
    Cell Mol Life Sci; 2019 Jan; 76(2):259-281. PubMed ID: 30343319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.